{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T23:49:31Z","timestamp":1794700171323,"version":"4.9.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged \u226470 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. Patients received 3 cycles of ibrutinib lead-in then 12 cycles of ibrutinib plus venetoclax (oral ibrutinib [420 mg\/d]; oral venetoclax [5-week ramp-up to 400 mg\/d]). The primary endpoint was complete response (CR) rate. Hypothesis testing was performed for patients without del(17p) with prespecified analyses in all treated patients. Secondary endpoints included undetectable minimal residual disease (uMRD) rates, progression-free survival (PFS), overall survival (OS), and safety. Of the 159 patients enrolled and treated, 136 were without del(17p). The median time on study was 27.9 months, and 92% of patients completed all planned treatment. The primary endpoint was met, with a CR rate of 56% (95% confidence interval [CI], 48-64) in patients without del(17p), significantly higher than the prespecified 37% minimum rate (P &amp;lt; .0001). In the all-treated population, CR rate was 55% (95% CI, 48-63); best uMRD rates were 77% (peripheral blood [PB]) and 60% (bone marrow [BM]); 24-month PFS and OS rates were 95% and 98%, respectively. At baseline, 21% of patients were in the high tumor burden category for tumor lysis syndrome (TLS) risk; after ibrutinib lead-in, only 1% remained in this category. The most common grade \u22653 adverse events (AEs) were neutropenia (33%) and hypertension (6%). First-line ibrutinib plus venetoclax represents the first all-oral, once-daily, chemotherapy-free FD regimen for patients with CLL. FD ibrutinib plus venetoclax achieved deep, durable responses and promising PFS, including in patients with high-risk features.<\/jats:p>","DOI":"10.1182\/blood.2021014488","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T20:31:20Z","timestamp":1645648280000},"page":"3278-3289","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":263,"title":["Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"first","affiliation":[{"name":"1Peter MacCallum Cancer Center, Melbourne, VIC, Australia;"},{"name":"2St. Vincent\u2019s Hospital, Melbourne, VIC, Australia;"},{"name":"3University of Melbourne, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-0899","authenticated-orcid":false,"given":"John N.","family":"Allan","sequence":"additional","affiliation":[{"name":"4Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-8298","authenticated-orcid":false,"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"5City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"6Moores Cancer Center, University of California San Diego, San Diego, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Jacobs","sequence":"additional","affiliation":[{"name":"7Levine Cancer Institute, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[{"name":"8Monash University, Clayton, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-401X","authenticated-orcid":false,"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"9Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"10ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-6149","authenticated-orcid":false,"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[{"name":"11University of Padova, Padova, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Bannerji","sequence":"additional","affiliation":[{"name":"12Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3584-8872","authenticated-orcid":false,"given":"Sharon","family":"Jackson","sequence":"additional","affiliation":[{"name":"13Middlemore Hospital, Auckland, New Zealand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryone J.","family":"Kuss","sequence":"additional","affiliation":[{"name":"14Flinders University and Medical Center, Bedford Park, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Moreno","sequence":"additional","affiliation":[{"name":"15Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Szafer-Glusman","sequence":"additional","affiliation":[{"name":"16Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Russell","sequence":"additional","affiliation":[{"name":"16Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Zhou","sequence":"additional","affiliation":[{"name":"16Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joi","family":"Ninomoto","sequence":"additional","affiliation":[{"name":"16Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Dean","sequence":"additional","affiliation":[{"name":"16Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"17Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"18Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy; and"},{"name":"19IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2022060215234678300_B1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia."},{"issue":"5","key":"2022060215234678300_B2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"2022060215234678300_B3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"issue":"26","key":"2022060215234678300_B4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med."},{"key":"2022060215234678300_B5","article-title":"VENCLEXTA (venetoclax tablets) for oral use [package insert]","year":"2020"},{"issue":"4","key":"2022060215234678300_B6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med."},{"issue":"19","key":"2022060215234678300_B7","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022060215234678300_B8","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"issue":"16","key":"2022060215234678300_B9","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res."},{"key":"2022060215234678300_B10","author":"Wang"},{"issue":"23","key":"2022060215234678300_B11","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood."},{"key":"2022060215234678300_B12","first-page":"3018","article-title":"Combinatorial treatment of chronic lymphocytic leukemia with ibrutinib and venetoclax is superior to treatment with single agents in the TCL1 mouse model","volume":"130","author":"Slinger","year":"2017","journal-title":"Blood."},{"issue":"25","key":"2022060215234678300_B13","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood."},{"issue":"1","key":"2022060215234678300_B14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med."},{"issue":"10","key":"2022060215234678300_B15","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia."},{"key":"2022060215234678300_B16","author":"Siddiqi","year":"2020."},{"issue":"34","key":"2022060215234678300_B17","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022060215234678300_B18","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol."},{"key":"2022060215234678300_B19","author":"Jain"},{"issue":"8","key":"2022060215234678300_B20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood.2020008608","article-title":"Venetoclax and ibrutinib for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"137","author":"Niemann","year":"2021","journal-title":"Blood."},{"key":"2022060215234678300_B21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-141716","article-title":"The addition of venetoclax to ibrutinib achieves a high rate of undetectable minimal residual disease in patients with high-risk CLL","volume":"136","author":"Thompson","year":"2020","journal-title":"Blood."},{"key":"2022060215234678300_B22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-136960","article-title":"Continued long term responses to ibrutinib + venetoclax treatment for relapsed\/refractory CLL in the blood cancer UK TAP CLARITY trial [abstract]","volume":"136","author":"Hillmen","year":"2020","journal-title":"Blood."},{"issue":"12","key":"2022060215234678300_B23","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood."},{"key":"2022060215234678300_B24","first-page":"5348","article-title":"Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase in peripheral blood lymphocytes","volume":"119","author":"Hallek","year":"2012","journal-title":"Blood."},{"issue":"4","key":"2022060215234678300_B25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia."},{"key":"2022060215234678300_B26","author":"National Cancer Institute","year":"2009."},{"issue":"19","key":"2022060215234678300_B27","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med."},{"issue":"7","key":"2022060215234678300_B28","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"issue":"23","key":"2022060215234678300_B29","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med."},{"issue":"9","key":"2022060215234678300_B30","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol."},{"issue":"24","key":"2022060215234678300_B31","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood-2013-11-538116","article-title":"Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL","volume":"123","author":"Strati","year":"2014","journal-title":"Blood."},{"issue":"4","key":"2022060215234678300_B32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022060215234678300_B33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood."},{"key":"2022060215234678300_B34","author":"Kater"},{"issue":"18","key":"2022060215234678300_B35","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"24","author":"Davids","year":"2018","journal-title":"Clin Cancer Res."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/22\/3278\/1900285\/bloodbld2021014488.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/22\/3278\/1900285\/bloodbld2021014488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T15:26:22Z","timestamp":1654183582000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/22\/3278\/484114\/Fixed-duration-ibrutinib-plus-venetoclax-for-first"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":35,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,6,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014488","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}